Navigation Links
IRIDEX Reports 2013 First Quarter Results

MOUNTAIN VIEW, Calif., May 2, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 30, 2013.

  • Ophthalmology revenues in the first quarter were $8.9 million, a first quarter record, compared to $8.3 million in the prior year period.
  • Gross margin for the first quarter was 47.3%, compared to 48.0% in the prior year period. Margins were impacted in the quarter by strong international sales through our distributor network with a product mix favoring laser systems, which have lower margins than the Company's consumable products.
  • Operating expenses were $3.8 million in the first quarter which were reduced to $3.3 million as a result of the Company receiving $0.5 million in the form of a cash distribution from an insurance carrier. This compares to $4.2 million in the prior year period.
  • Income from continuing operations for the first quarter was $0.9 million, or $0.10 per basic share ($0.09 per diluted share), compared with a loss from continuing operations of $0.3 million, or $0.03 loss per basic and diluted share, in the prior year period.  
  • Guidance for second quarter 2013: The Company expects to achieve revenues between $8.9 million and $9.2 million and gross margins between 47% and 49%. Operating expenses are expected to be between $4.0 million and $4.2 million.
  • CEO William M. Moore said, "We demonstrated good execution in the first quarter as the Company increased revenues and profits.  In addition to these commercial and operational gains, we completed the successful product launch of TxCell™, our high speed scanning laser delivery system, and concluded negotiation of a beneficial selling and supply chain agreement with Peregrine Surgical. Of particulate note, the percentage of customers ordering new lasers with MicroPulse™ in the first quarter was approximately double that seen in last year's period, giving us one more indication that we are edging towards a technology-driven tipping point in the market."

    Moore continued, "We will look to grow and increase profitability, invest in products that our customers want and that can be delivered to the market rapidly, and be opportunistic in acquiring or partnering with ophthalmic companies that have developed excellent technologies. Peregrine is a great example of such a partnership, as it allows us to market additional consumable products at different price points.  The relationship should lower our supply chain costs and we are already, jointly, working on new product initiatives in the high-margin consumable product category."

    The preceding commentary relates to the results of the Company's continuing ophthalmology business. In February 2012, the Company sold its aesthetics laser business and the financial statements reflect the results of its aesthetics laser business as discontinued operations.

    Recent Business Highlights

  • The Company entered into a global distribution and supply agreement with Peregrine Surgical, Ltd., a privately held company based in New Britain, Pennsylvania. Under the agreement, IRIDEX will become a worldwide distributor for Peregrine labeled products and Peregrine Surgical will become part of the IRIDEX supply chain for the manufacture of certain IRIDEX products.
  • Following a fourth quarter 2012 FDA 510(k) CE clearance, the Company commenced its full commercial launch of its TxCell Scanning Laser Delivery System. This new product saves significant time in a variety of laser photocoagulation procedures by allowing physicians to deliver the laser in a multi-spot scanning mode, a more efficient method for these procedures than the traditional single spot mode.  Management believes that the clinical and practice benefits of this technology will accelerate the adoption of the proprietary MicroPulse technology as it applies to several clinical procedures.
  • February 28, 2013 the Board approved a new one year $3.0 million stock repurchase program.
  • Conference Call IRIDEX management will conduct a conference call later today, Thursday, May 2 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (877) 941-2927 (U.S.) or (480) 629-9725 (International) and quoting Conference ID 4615855, or by visiting the Company's website at A telephone replay will be available beginning on Thursday, May 2, 2013 through Thursday, May 9, 2013 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4615855. In addition, later today an archived version of the webcast will be available on the Company's website at

    About IRIDEXIRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries. For further information, visit the Company's website at

    Safe Harbor StatementThis announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended, relating to the size and growth of and trends in the markets in which the Company operates, including market adoption of new technologies; the success of the Company's development, marketing and sales efforts, including the adoption of MicroPulse laser therapy devices; the Company's growth strategy; the Company's acquisition strategy; the Company's sales revenue growth, operational plans, and profitability expectations; the Company's projected fiscal 2013 financial results; and the Company's share repurchase program. These statements are not guarantees of future performance and actual results may differ materially from those described in these forward-looking statements as a result of a number of factors. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended December 29, 2012 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.


     IRIDEX Corporation

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)(unaudited)Three Months EndedMarch 30,March 31, 20132012Total revenues

    8,305Cost of revenues

    4,7084,319Gross profit

    4,2313,986Operating expenses:Research and development

    9961,182Sales and marketing

    1,6251,864General and administrative

    1,1861,176Proceeds from demutualization of insurance carrier

    (473)-Total operating expenses

    3,3344,222Income (loss) from continuing operations

    897(236)  Other expense, net

    (18)(27)Income (loss) from continuing operations before provision for income taxes

    879(263)Provision for income taxes

    52  Income (loss) from continuing operations, net of tax

    874(265)  Loss from discontinued operations, net of tax

    -(162)  Gain on sale of discontinued operations, net of tax

    -2,032  Income from discontinued operations, net of tax

    -1,870Net income

    ,605Net income (loss) per share: Basic -  Continuing operations

    $0.10($0.03)  Discontinued operations

    0.000.21  Net income

    $0.10$0.18 Diluted -  Continuing operations

    $0.09($0.03)  Discontinued operations

    0.000.21  Net income

    $0.09$0.18Weighted average shares used in computing net income (loss) per share  - basic

    8,5118,933Weighted average shares used in computing net income (loss) per share  - diluted

    9,8028,933IRIDEX Corporation

    Condensed Consolidated Balance Sheets

    (In thousands)

    (unaudited)March 30, December 29,20132012AssetsCurrent assets:Cash and cash equivalents

    ,901Accounts receivable, net


    8,1478,035Prepaid expenses and other current assets

    1,1231,129Current assets of discontinued operations

    510510Total current assets

    27,39227,055Property and equipment, net

    440483Other intangible assets, net


    533533Other long-term assets

    298287Total assets

    28,912Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable

    2,105Accrued compensation

    1,4421,563Accrued expenses

    1,3721,242Accrued warranty

    446453Deferred revenue

    9431,004Total current liabilities

    5,4836,367Long-term liabilities:Other long-term liabilities

    542640Total liabilities

    6,0257,007Stockholders' equity:Convertible preferred stock

    55Common stock

    9594Additional paid-in capital

    39,30538,958Accumulated deficit

    (16,278)(17,152)Total stockholders' equity

    23,12721,905Total liabilities and stockholders' equity



    SOURCE IRIDEX Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries
    2. IRIDEX Announces First Quarter 2013 Conference Call and Release Date
    3. IRIDEX Announces Global Distribution and Supply Agreement with Peregrine Surgical, Ltd.
    4. IRIDEX Reports Record 2012 Fourth Quarter Results
    5. IRIDEX Announces Fourth Quarter and Full Year 2012
    6. IRIDEX Announces Preliminary Unaudited Revenues for 2012 Fourth Quarter and Year End
    7. IRIDEX Corporation Announces Preliminary Results of its Tender Offer
    8. IRIDEX Announces FDA 510(k) and CE Clearance of New Laser Delivery System for Fast, Non-invasive Treatment of Serious Retinal Diseases
    9. QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
    10. IRIDEX Announces Tender Offer to Purchase up to 487,500 Shares of its Common Stock
    11. IRIDEX Reports 2012 Third Quarter Results
    Post Your Comments:
    (Date:10/8/2015)... October 8, 2015 " Biomedical ... Growth, Trends and Forecast 2014 - 2022 " , ... 2.63 billion in 2013 and is anticipated to expand at ... USD 4.00 billion in 2022. --> " ... Share, Growth, Trends and Forecast 2014 - 2022 " ...
    (Date:10/8/2015)... N.C. , Oct. 8, 2015  Clariant, a world ... Packaging manufacturing facility in Belen, New Mexico ... for healthcare applications, including desiccant canisters and packets ... Belen plant is the second Clariant site – ... – to meet the ISO 15378:2011 standards, following only the ...
    (Date:10/8/2015)... , Oct. 8, 2015  Nektar Therapeutics (Nasdaq: ... pain and oncology portfolio during an Investor and Analyst ... p.m. Eastern Time in New York City ... of the NKTR-214 Phase 1/2 clinical program and biomarker ... cytokine designed to preferentially stimulate the production of CD8-positive ...
    Breaking Medicine Technology:
    ... SHP ) ("ShangPharma" or the "Company"), a ... company, today announced that it will release its unaudited ... ended December 31, 2011 on March 13, 2012. Management ... at 08:00AM New York Time on March 13, 2012 ...
    ... 28, 2012  Based on its recent analysis of ... Brainsway with the 2012 Global Frost & Sullivan ... Magnetic Stimulation (dTMS) is the only non-invasive technique ... depression and other neuro-psychiatric disorders without causing any ...
    Cached Medicine Technology:
    (Date:10/9/2015)... , ... October 09, 2015 , ... With the FCPX ... pop grades to footage. A LUT is a Lookup Table that contains a mathematical ... color indicated by the table. This pack comes with 60 vibrant CUBE LUT files. ...
    (Date:10/9/2015)... ... October 09, 2015 , ... ... in The Tennessean's eighth annual Toast of Music City, a reader’s choice awards ... residents nominated and cast votes for their favorite businesses in over 200 categories, ...
    (Date:10/9/2015)... ... ... On Saturday, September 26, 2015, 48-year-old MS survivor and entrepreneur Lucie B won ... USA and Sweden in the Speed and Power events, which consisted of 30-Second Single ... 1 Silver and 4 Gold Medals. , “I remember looking at my competitors and ...
    (Date:10/9/2015)... ... 2015 , ... "As a nurse, I care for male patients who struggle ... wear large diapers or pads. We came up with this as a better alternative ... leaking from the tip of the penis. This prevents stains from forming on underwear ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Santa Rosa Consulting and The ... MD Anderson prepares to go-live on the Epic platform in March of 2016. Both ... Santa Rosa will execute the contract by supporting Scheduling Appointment Conversion and the Go-Live. ...
    Breaking Medicine News(10 mins):
    ... eye of now co-editor Rick Drake and colleagues at the ... now the highest ranking journal in science education? If ... correct! As AAA publisher Wiley-Blackwell put it in a ... as the number 1 ranked journal in Education, Scientific Disciplines." ...
    ... scientists at Duke University Medical Center and Johns Hopkins ... of drug therapy to treat the second most common ... been looking for the primary cancer genes involved in ... that held the probable mutations, but not the particular ...
    ... Summer for most people means time spent outdoors, which ... arthropod-borne diseases, such as "rickettsial diseases" infectious diseases ... fleas, ticks and mites. Now a $1.6 million ... enable an entomologist at the University of California, Riverside ...
    ... Southwestern Medical Center researchers may suggest new strategies for successful ... such as leukemia, lymphoma and myeloma. The study, published ... the first time that adult blood stem cells can be ... rejection. It also opens up further studies in stem cell ...
    ... and are famous for their "work hard, play ... employees healthier too? According to a Tel Aviv University ... health benefits. Dr. Sharon Toker of the ... School of Business Administration says that employees who believe ...
    ... By Ellin Holohan HealthDay Reporter , THURSDAY, ... antidepressants than ever before to deal with everyday stress, ... to patients with no mental health diagnosis, a new ... Lexapro are now the third most widely prescribed group ...
    Cached Medicine News:
    Incontinence Pessaries...
    Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
    The Set comes with a cross reference chart that translates ring size into the correct size of other EvaCare pessaries. The Fitting Set can be disinfected in three ways: autoclaved, boiled or cold ste...
    The donut pessary is designed for third degree prolapse as well as cystocele and rectocele. The soft donut can be compressed for insertion. It is available in seven sizes....
    Medicine Products: